HUP0000833A3 - Treatment of lupus nephritis with anti-cd40l compounds - Google Patents
Treatment of lupus nephritis with anti-cd40l compoundsInfo
- Publication number
- HUP0000833A3 HUP0000833A3 HU0000833A HUP0000833A HUP0000833A3 HU P0000833 A3 HUP0000833 A3 HU P0000833A3 HU 0000833 A HU0000833 A HU 0000833A HU P0000833 A HUP0000833 A HU P0000833A HU P0000833 A3 HUP0000833 A3 HU P0000833A3
- Authority
- HU
- Hungary
- Prior art keywords
- treatment
- lupus nephritis
- cd40l compounds
- cd40l
- compounds
- Prior art date
Links
- 208000005777 Lupus Nephritis Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3467397P | 1997-01-10 | 1997-01-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0000833A2 HUP0000833A2 (en) | 2000-07-28 |
| HUP0000833A3 true HUP0000833A3 (en) | 2001-09-28 |
Family
ID=21877889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0000833A HUP0000833A3 (en) | 1997-01-10 | 1997-12-31 | Treatment of lupus nephritis with anti-cd40l compounds |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20030031668A1 (enExample) |
| EP (2) | EP1357131A3 (enExample) |
| JP (1) | JP2001508441A (enExample) |
| KR (2) | KR20000070034A (enExample) |
| CN (2) | CN1572325A (enExample) |
| AU (1) | AU5709798A (enExample) |
| BR (1) | BR9714523A (enExample) |
| CA (1) | CA2277222A1 (enExample) |
| CZ (1) | CZ297680B6 (enExample) |
| EA (2) | EA006314B1 (enExample) |
| EE (1) | EE9900273A (enExample) |
| HU (1) | HUP0000833A3 (enExample) |
| IL (1) | IL130784A0 (enExample) |
| IS (1) | IS5100A (enExample) |
| NO (1) | NO993274L (enExample) |
| NZ (1) | NZ337072A (enExample) |
| PL (1) | PL190663B1 (enExample) |
| TR (7) | TR200001251T2 (enExample) |
| WO (1) | WO1998030240A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
| CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| US6340459B1 (en) | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
| KR20010072564A (ko) * | 1998-04-03 | 2001-07-31 | 존 에프. 카바나프 | 루푸스 및 관련된 신장 질환의 치료 및/또는 반전에사용되는 안티 ｇｐ39 항체의 용도 |
| IL126681A0 (en) * | 1998-10-21 | 1999-08-17 | Opperbas Holding Bv | Treatment of trauma-related conditions |
| WO2000036103A1 (en) | 1998-12-14 | 2000-06-22 | Genetics Institute, Inc. | Cytokine receptor chain |
| US7553487B2 (en) | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
| US6171795B1 (en) * | 1999-07-29 | 2001-01-09 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to CD40ligand |
| WO2001068133A1 (en) * | 2000-03-14 | 2001-09-20 | Genetics Institute, Inc. | Use of rapamycin and agents that inhibit b7 activity in immunomodulation |
| AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| WO2002022212A2 (en) * | 2000-09-18 | 2002-03-21 | Idec Pharmaceuticals Corporation | Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| EP3718564B1 (en) | 2003-12-23 | 2023-10-11 | Genentech, Inc. | Novel anti-il 13 antibodies and uses thereof |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| CN100369932C (zh) * | 2005-04-07 | 2008-02-20 | 苏州大学 | 抗人cd154单克隆抗体及其应用 |
| US8435514B2 (en) | 2008-12-05 | 2013-05-07 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| US9044459B2 (en) | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| US20130310266A1 (en) * | 2010-09-03 | 2013-11-21 | Immport Therapeutics, Inc. | Methods and Compositions For The Diagnosis And Treatment Of Cancer and Autoimmune Disorders |
| CA3174012A1 (en) | 2013-09-13 | 2015-03-19 | Genentech, Inc. | Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products |
| IL244149B2 (en) | 2013-09-13 | 2025-09-01 | Genentech Inc | Methods and compositions containing purified recombinant polypeptides |
| US11111284B2 (en) | 2014-08-21 | 2021-09-07 | The General Hospital Corporation | Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| JP2018526443A (ja) * | 2015-08-31 | 2018-09-13 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 全身性エリテマトーデスを治療するためのｌｇａｌｓ３ｂｐの調節方法 |
| EP3630843A2 (en) | 2017-05-24 | 2020-04-08 | ALS Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US6440418B1 (en) * | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| EP0874637A1 (en) * | 1996-01-16 | 1998-11-04 | The Trustees of Columbia University in the City of New York | Therapeutic applications of t-bam (cd40l) technology to treat inflammatory kidney diseases |
| WO1997034473A1 (en) * | 1996-03-21 | 1997-09-25 | The Trustees Of Columbia University In The City Of New York | Craf1 (traf-3) isoforms and uses thereof |
-
1997
- 1997-12-31 KR KR1019997006253A patent/KR20000070034A/ko not_active Ceased
- 1997-12-31 IL IL13078497A patent/IL130784A0/xx unknown
- 1997-12-31 JP JP53090198A patent/JP2001508441A/ja not_active Ceased
- 1997-12-31 HU HU0000833A patent/HUP0000833A3/hu unknown
- 1997-12-31 TR TR2000/01251T patent/TR200001251T2/xx unknown
- 1997-12-31 PL PL97334495A patent/PL190663B1/pl not_active IP Right Cessation
- 1997-12-31 KR KR1020057013113A patent/KR100618081B1/ko not_active Expired - Fee Related
- 1997-12-31 TR TR2000/01247T patent/TR200001247T2/xx unknown
- 1997-12-31 CZ CZ0244499A patent/CZ297680B6/cs not_active IP Right Cessation
- 1997-12-31 TR TR2000/01246T patent/TR200001246T2/xx unknown
- 1997-12-31 BR BR9714523-8A patent/BR9714523A/pt not_active Application Discontinuation
- 1997-12-31 AU AU57097/98A patent/AU5709798A/en not_active Abandoned
- 1997-12-31 NZ NZ337072A patent/NZ337072A/xx unknown
- 1997-12-31 TR TR1999/02191T patent/TR199902191T2/xx unknown
- 1997-12-31 EP EP03014404A patent/EP1357131A3/en not_active Withdrawn
- 1997-12-31 TR TR2000/01248T patent/TR200001248T2/xx unknown
- 1997-12-31 CN CNA2004100353620A patent/CN1572325A/zh active Pending
- 1997-12-31 EP EP97953325A patent/EP0948355A1/en not_active Withdrawn
- 1997-12-31 CN CN97181948A patent/CN1247472A/zh active Pending
- 1997-12-31 EA EA199900636A patent/EA006314B1/ru not_active IP Right Cessation
- 1997-12-31 TR TR2000/01249T patent/TR200001249T2/xx unknown
- 1997-12-31 CA CA002277222A patent/CA2277222A1/en not_active Abandoned
- 1997-12-31 TR TR2000/01250T patent/TR200001250T2/xx unknown
- 1997-12-31 EA EA200501076A patent/EA200501076A1/ru unknown
- 1997-12-31 EE EEP199900273A patent/EE9900273A/xx unknown
- 1997-12-31 WO PCT/US1997/023482 patent/WO1998030240A1/en not_active Ceased
-
1999
- 1999-06-30 IS IS5100A patent/IS5100A/is unknown
- 1999-07-01 NO NO993274A patent/NO993274L/no not_active Application Discontinuation
-
2002
- 2002-09-27 US US10/260,639 patent/US20030031668A1/en not_active Abandoned
-
2006
- 2006-09-25 US US11/527,700 patent/US20070190053A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0000833A3 (en) | Treatment of lupus nephritis with anti-cd40l compounds | |
| GB9705349D0 (en) | Treatment of effluent streams | |
| GB9606638D0 (en) | Treatment of solid containing material derived from effluent | |
| ZA983176B (en) | Therapeutic compounds | |
| IL113248A0 (en) | Use of alpha - 1c specific compounds | |
| GB9701674D0 (en) | Use of organic compounds | |
| GB9725114D0 (en) | Treatment of pruritus | |
| GB9616037D0 (en) | Treatment of solid containing material derived from effluent | |
| GB9716345D0 (en) | Therapeutic compounds | |
| HK1025041A (en) | Treatment of lupus nephritis with anti-cd40l compounds | |
| GB9716344D0 (en) | Therapeutic compounds | |
| GB9716347D0 (en) | Therapeutic compounds | |
| HK1023068A (en) | Treatment of iupus nephritis with anti-cd40l compounds | |
| IL117813A0 (en) | Use of heterocyclic compounds | |
| GB2301353B (en) | Treatment of undesirable halogenated organic compounds | |
| GB2331514B (en) | Effluent treatment | |
| IL120955A0 (en) | Treatment of osteoporosis | |
| GB2365419B (en) | Treatment of effluents | |
| ZA9811524B (en) | Treatment of effluent | |
| GB9722026D0 (en) | Use of compounds | |
| GB9810855D0 (en) | Use of compounds | |
| GB2316942B (en) | Purification of pentafluoroethane | |
| HUP9902845A3 (en) | Novel treatment of leptine resistance | |
| PL327430A1 (en) | Set of shaped components | |
| GB9503795D0 (en) | Use of organic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |